Prophylactic Administration of Tirofiban for Preventing Thromboembolic Events in Stent-assisted Coiling and Flow Diversion Treatments of Unruptured Intracranial Aneurysms
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2/Phase 3
SUMMARY
To explore whether administering tirofiban in stent-assisted coiling/flow diverting treatments for participants with unruptured intracranial aneurysms can reduce new ischemic lesions on postoperative DWI sequences compared to conventional dual antiplatelet therapy.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 80
Healthy Volunteers: f
View:
• Ages 18-80.
• Participants with unruptured cerebral aneurysms eligible for stent-assisted coiling or flow diversion devices.
• Completement of preoperative antiplatelet preparation.
• Signed informed consent.
Locations
Other Locations
China
Beijing Tiantan Hospital
RECRUITING
Beijing
Contact Information
Primary
Qianmei Jiang
13882701231@163.com
13882701231
Backup
Lian Liu
liuliandaxiang@126.com
Time Frame
Start Date: 2024-03-04
Estimated Completion Date: 2025-06-01
Participants
Target number of participants: 190
Treatments
Experimental: Tirofiban group
After femoral artery puncture, initial infusion of 0.4μg/kg body weight/minute over 30 minutes, followed by a continuous infusion of 0.1μg/kg body weight/minute for 24 hours.
Placebo_comparator: Standard medical care
Routine dual antiplatelet therapy (aspirin 100 mg/day, clopidogrel 75 mg/day)
Related Therapeutic Areas
Sponsors
Leads: Beijing Tiantan Hospital